Drug Profile


Alternative Names: DSP-225289; SEP 225289; SEP-0225289; SEP-289

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Sepracor
  • Developer Sepracor; Sunovion Pharmaceuticals
  • Class Amines; Antidepressants; Cyclobutanes; Naphthalenes; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder; Eating disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 02 Feb 2017 Sunovion completes a phase III trial (In children, In adolescents) for Attention deficit hyperactivity disorder in USA (NCT02457819)
  • 01 Feb 2017 Sunovion completes a phase III trial for Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT02734693)
  • 14 Jan 2017 Efficacy and adverse event data from a phase II/III trial in Attention-deficit hyperactivity disorder released by Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top